Clinical Trials Logo

Pulmonary Carcinoid Tumor clinical trials

View clinical trials related to Pulmonary Carcinoid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT04915144 Withdrawn - Clinical trials for Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).

NCT ID: NCT02259725 Completed - Insulinoma Clinical Trials

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Start date: August 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00093782 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00084461 Terminated - Insulinoma Clinical Trials

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy